Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 21, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on July 21, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $524.37 ($62,924) on July 21, 2026; holds 333,823 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $526.24 ($84,198) on July 21, 2026; holds 333,663 after (Indirect).
- Open-market sale: disposed of 240 Common Stock at $527.46 ($126,590) on July 21, 2026; holds 333,423 after (Indirect).
- Open-market sale: disposed of 509 Common Stock at $529.55 ($269,541) on July 21, 2026; holds 332,914 after (Indirect).
- Open-market sale: disposed of 1,926 Common Stock at $530.50 ($1,021,743) on July 21, 2026; holds 330,988 after (Indirect).
- Open-market sale: disposed of 2,605 Common Stock at $531.52 ($1,384,598) on July 21, 2026; holds 328,383 after (Indirect).
- Open-market sale: disposed of 360 Common Stock at $532.47 ($191,688) on July 21, 2026; holds 328,023 after (Indirect).
- Open-market sale: disposed of 640 Common Stock at $533.58 ($341,490) on July 21, 2026; holds 327,383 after (Indirect).
- Open-market sale: disposed of 1,760 Common Stock at $534.61 ($940,922) on July 21, 2026; holds 325,623 after (Indirect).
- Open-market sale: disposed of 341 Common Stock at $535.44 ($182,586) on July 21, 2026; holds 325,282 after (Indirect).
- Open-market sale: disposed of 839 Common Stock at $536.37 ($450,018) on July 21, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on July 21, 2026; holds 303,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,056,298 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-21 | Option exercise/conversion | Common Stock | 9,500 | $135 | $1.3M | 333,943 |
| 2026-07-21 | Open-market sale | Common Stock | 120 | $524 | $62.9K | 333,823 |
| 2026-07-21 | Open-market sale | Common Stock | 160 | $526 | $84.2K | 333,663 |
| 2026-07-21 | Open-market sale | Common Stock | 240 | $527 | $126.6K | 333,423 |
| 2026-07-21 | Open-market sale | Common Stock | 509 | $530 | $269.5K | 332,914 |
| 2026-07-21 | Open-market sale | Common Stock | 1,926 | $531 | $1.0M | 330,988 |
| 2026-07-21 | Open-market sale | Common Stock | 2,605 | $532 | $1.4M | 328,383 |
| 2026-07-21 | Open-market sale | Common Stock | 360 | $532 | $191.7K | 328,023 |
| 2026-07-21 | Open-market sale | Common Stock | 640 | $534 | $341.5K | 327,383 |
| 2026-07-21 | Open-market sale | Common Stock | 1,760 | $535 | $940.9K | 325,623 |
| 2026-07-21 | Open-market sale | Common Stock | 341 | $535 | $182.6K | 325,282 |
| 2026-07-21 | Open-market sale | Common Stock | 839 | $536 | $450.0K | 324,443 |
| 2026-07-21 | Option exercise/conversion | Stock Option | 9,500 | — | — | 303,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-21 | Option exercise/conversion (9,500 shares) |
| 2026-07-21 | Open-market sale (120 shares) |
| 2026-07-21 | Open-market sale (160 shares) |
| 2026-07-21 | Open-market sale (240 shares) |
| 2026-07-21 | Open-market sale (509 shares) |
| 2026-07-21 | Open-market sale (1,926 shares) |
| 2026-07-21 | Open-market sale (2,605 shares) |
| 2026-07-21 | Open-market sale (360 shares) |
| 2026-07-21 | Open-market sale (640 shares) |
| 2026-07-21 | Open-market sale (1,760 shares) |
| 2026-07-21 | Open-market sale (341 shares) |
| 2026-07-21 | Open-market sale (839 shares) |
| 2026-07-21 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.